Elite Journal of Immunology. Volume 2 issue 2(2024), Pp. 29-42 https://epjournals.com/journals/EJI Citation: Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Management Strategies. Elite Journal of Immunology, 2024; 2(2): 29-42 1 P-Selectin and Immune Activation in HIV: Clinical Management Strategies * Emmanuel Ifeanyi Obeagu 1 and Getrude Uzoma Obeagu 2 1 Department of Medical Laboratory Science, Kampala International University, Uganda. 2 School of Nursing Science, Kampala International University, Uganda. * Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002- 4538-0161 Abstract P-Selectin, a critical cell adhesion molecule implicated in leukocyte-endothelial interactions, has emerged as a significant player in the realm of immune activation in HIV infection. This review article explores the intricate relationship between P-Selectin and immune activation in HIV, with a focus on its clinical management implications. Chronic immune activation is a hallmark of HIV pathogenesis, contributing to disease progression and adverse clinical outcomes. P-Selectin, expressed on activated endothelial cells and platelets, facilitates leukocyte recruitment and exacerbates endothelial dysfunction, thus perpetuating immune dysregulation in HIV. Elevated levels of soluble P-Selectin have been associated with disease progression, cardiovascular events, and mortality in HIV-infected individuals. Targeting P-Selectin represents a promising therapeutic strategy to mitigate immune activation and improve clinical outcomes in HIV. Preclinical studies have demonstrated the efficacy of P-Selectin inhibitors in reducing viral replication and immune activation in HIV models. However, further research is warranted to validate these findings in clinical settings and optimize therapeutic strategies. Understanding the role of P-Selectin in HIV- associated immune dysregulation is crucial for developing innovative approaches to manage HIV infection and its associated complications. This review underscores the potential of targeting P- Selectin as a novel therapeutic avenue in the clinical management of HIV, highlighting the need for future research to translate these findings into clinical practice and improve patient care. Keywords: P-Selectin, immune activation, HIV, clinical management, endothelial dysfunction, platelet activation, leukocyte recruitment, therapeutic interventions